| IC50 (nM) |
---|
CEM | CEM/P | [ratio] | MOLT4 | MOLT4/P | [ratio] |
---|
PDX | 0.6 | 20 | 33 | 2.4 | 80 | 33 |
MTX | 8.5 | 18 | 2.1 | 40 | 120 | 3.0 |
FDSa | 4.2 | 1.6 | 0.4 | 8.0 | 7.0 | 0.9 |
AraC | 30 | 35 | 1.2 | 24 | 2.0 | 0.1 |
BOR | 3.7 | 6.5 | 1.8 | 5.9 | 6.5 | 1.1 |
LBH589 | 5.5 | 5.0 | 0.9 | 5.5 | 6.2 | 1.1 |
DAC | 6.5 × 103 | 2.3 × 103 | 0.4 | 3.7 × 103 | 750 | 0.2 |
- IC50 50% growth inhibitory concentration, PDX pralatrexate, MTX methotrexate, FDS forodesine, AraC cytarabine, BOR bortezomib, LBH589 panobinostat, DAC 5-aza-2′-deoxycytidine
- aIn assays using FDS, cells were incubated with deoxyguanosine (10 μM) because the cytotoxicity of FDS requires the presence of deoxyguanosine in vitro